

Special Issue

Translational Research and Novel Therapeutics in Cutaneous Melanoma

Message from the Guest Editors

There has been an alarming increase in the global incidence of melanoma. Previous research in the immunology and pathophysiology of melanoma has led to groundbreaking discoveries, facilitating the development of innovative and personalized treatment modalities. These advancements are contributing to a reduction in mortality rates and an improvement in the quality of life for patients diagnosed with malignant melanoma. Despite these significant discoveries, there remains a critical need for a deeper understanding of tumor pathology to develop novel therapeutic agents.

This Special Issue aims to present the most recent advances in the field of translational research and novel therapeutics in cutaneous melanoma and their implications for the future care of melanoma patients. We invite colleagues worldwide to submit their research in this area in the form of original articles and state-of-the-art reviews. Submissions may include topics such as the immunopathology of melanoma, novel biomarkers, cell therapies, tumor vaccines, and emerging technologies for the early diagnosis of cutaneous melanoma (AI and digital dermoscopy) to be considered for inclusion in this Special Issue.

Guest Editors

Dr. Maja Tolušić Levak


1. Department of Dermatovenereology, University Hospital Osijek, Osijek, Croatia
2. Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia

Prof. Dr. Martina Mihalj

1. Department of Dermatovenereology, University Hospital Osijek, Osijek, Croatia
2. Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia

Deadline for manuscript submissions

31 December 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/213493

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

[jpm](https://mdpi.com/journal/)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).